Serum microRNA-133b is associated with low ceruloplasmin levels in Parkinson's disease

Zhao, Na; Jin, Lirong; Fei, Guoqiang; Zeng, Zheng; Zhong, Chunjiu

doi:10.1016/j.parkreldis.2014.08.016

Cited by 42 publications

(33 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of miR-30c is decreased in PD, respectively, in PBMCs (Martins et al, 2011) and serum (Vallelunga et al, 2014). Decreased levels of miR-133b and miR-433 in plasma of PD as shown in the current study are in line with two previous reports, respectively in serum and CSF (Burgos et al, 2014; Zhao et al, 2014). Also, consistent with our results, miR-153 and miR-34b are not reported to be changed in fluids of PD.…”

Section: Discussionsupporting

confidence: 94%

“…The deficiency of miR-133b in PD is further confirmed using laser microdissected postmortem dopaminergic neurons in a case–control study (Sonntag, 2010). In accordance, miR-133b level is significantly decreased in plasma/serum of PD patients as shown in the current study and a previous report (Zhao et al, 2014). Interestingly, different from the above in vitro model (Kim et al, 2007), miR-133b null mice exhibit normal numbers of midbrain dopaminergic neurons during development and aging along with unchanged Pitx3 expression and dopamine release in the striatum (Heyer et al, 2012).…”

Section: Discussionsupporting

confidence: 93%

“…However, further studies are needed from populations of wider age range since the age of participants in this study resides in a narrow range. It is surprising that changes in miR-433 and miR-133b expression are not associated with PD severity, although this seems not a sole case (Zhao et al, 2014; Li et al, 2017). Further studies are needed with larger sample size for each stage.…”

Section: Discussionmentioning

confidence: 97%

“…Although there is no consensus on the miRNA loading control (Laurent et al, 2015), many studies have used nucleolar RNA U6 as an internal control to normalize circulating miRNAs (Ai et al, 2010; Wang et al, 2013; Zhao et al, 2014), while some studies simply follow a consistent reaction system using no normalization controls as noted earlier (Chen et al, 2008; Ren et al, 2013). Besides, endogenous miR-16-5p, considered to be similar among individuals in most cases, was occasionally used as an internal control (Song et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Reduced Circulating Levels of miR-433 and miR-133b Are Potential Biomarkers for Parkinson’s Disease

Zhang

Yang

et al. 2017

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Aberrant expression of microRNA (miRNA) in tissues may lead to altered level in circulation. Considerable evidence has suggested that miRNA deregulation is involved in the pathogenesis of Parkinson’s disease (PD). In this study, we screened a set of PD-associated miRNAs and aimed to identify differentially expressed miRNAs in plasma of PD patients and to evaluate their potentiality to serve as PD biomarkers. A total of 95 subjects consisting of 46 sporadic PD cases and 49 controls were recruited. Plasma levels of six miRNAs including miR-433, miR-133b, miR-34b, miR-34c, miR-153, and miR-7 were evaluated using reverse transcribed quantitative PCR, among which we found that miR-34c and miR-7 were below detection limit under our condition. The results showed that levels of circulating miR-433 (P = 0.003) and miR-133b (P = 0.006), but not miR-34b and miR-153, were reduced in PD patients. miR-433 and miR-133b were strongly correlated in both control and PD groups (rs = 0.87 and 0.85, respectively). The correlation between miR-34b and miR-153 expressions was significantly reduced (P < 0.05) in the PD group. Although miR-433 and miR-133b were likely to be functionally complimentary as suggested by Pathway and Gene Ontology analyses, these two miRNAs per se might not be sufficient to predict PD. No correlation was observed between the four miRNAs and age or severity of disease. Collectively, our results demonstrate that circulating miR-433 and miR-133b are significantly altered in PD and may serve as PD biomarkers.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Reduced Circulating Levels of miR-433 and miR-133b Are Potential Biomarkers for Parkinson’s Disease

Zhang

Yang

et al. 2017

Front. Cell. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Several miRNAs, such as miR‐15b, miR‐181a, miR‐185, miR‐195, and miR‐221; miR‐141, miR‐146b‐5p, miR‐193a‐3p, and miR‐214; and circulating miR‐24, miR‐34b, and miR‐148b were identified as the biomarker for PD. Also, significantly decreased serum miR‐133b levels were correlated with low serum ceruloplasmin level in PD patients, and circulating miR‐29c, miR‐29a, and miR‐19b levels were downregulated in idiopathic PD . Therefore, these miRNAs are considered as novel biomarkers and potential therapy targets.…”

Section: Introductionmentioning

confidence: 99%

Serum miR‐221 serves as a biomarker for Parkinson's disease

Wang

et al. 2016

Cell Biochemistry & Function

View full text Add to dashboard Cite

Parkinson's disease (PD) is the common age-related neurodegenerative disorder. Sensitive, noninvasive biomarkers that facilitate PD diagnosis and stage assignment are currently unavailable. This study aims to investigate the potential of 16 previous reported PD-associated miRNAs as novel biomarkers for PD. The expression of 16 serum miRNAs was measured by quantitative reverse transcriptase polymerase chain reaction in 138 PD patients and 112 control populations. Analyses were undertaken to assess the specificity and sensitivity of miRNAs to predict PD. In addition, the relationship between deregulated miRNAs and Part III of the United Parkinson's Disease Rating Scale (UPDRS-III) and Part V of the UPDRS (UPDRS-V; the modified Hoehn and Yahr staging of PD) in PD patients was also assessed. It was found that the serums miR-29c, miR-146a, miR-214, and miR-221 were significantly decreased in PD patients compared with healthy control populations. In addition, serum miR-221 was positively correlated with UPDRS-III (r = .4702) and UPDRS-V (r = .4788) score in PD patients. Furthermore, the receiver operating characteristic result of serum miR-221 for prediction of PD was 0.787. Our preliminary findings indicate that downregulated serum miR-221 might be a potential biomarker for PD evaluation.

show abstract

Meta‐analyses identify differentially expressed microRNAs in Parkinson's disease

Schulz

Takousis

Wohlers

et al. 2019

Annals of Neurology

View full text Add to dashboard Cite

Objective: MicroRNA (miRNA)-mediated (dys)regulation of gene expression has been implicated in Parkinson's disease (PD), although results of miRNA expression studies remain inconclusive. We aimed to identify miRNAs that show consistent differential expression across all published expression studies in PD. Methods: We performed a systematic literature search on miRNA expression studies in PD and extracted data from eligible publications. After stratification for brain, blood, and cerebrospinal fluid (CSF)-derived specimen, we performed meta-analyses across miRNAs assessed in three or more independent data sets. Meta-analyses were performed using effect-size-and p-value-based methods, as applicable. Results: After screening 599 publications, we identified 47 data sets eligible for meta-analysis. On these, we performed 160 meta-analyses on miRNAs quantified in brain (n = 125), blood (n = 31), or CSF (n = 4). Twenty-one meta-analyses were performed using effect sizes. We identified 13 significantly (Bonferroni-adjusted α = 3.13 × 10 -4 ) differentially expressed miRNAs in brain (n = 3) and blood (n = 10) with consistent effect directions across studies. The most compelling findings were with hsa-miR-132-3p (p = 6.37 × 10 -5 ), hsa-miR-497-5p (p = 1.35 × 10 -4 ), and hsa-miR-133b (p = 1.90 × 10 -4 ) in brain and with hsa-miR-221-3p (p = 4.49 × 10 -35 ), hsa-miR-214-3p (p = 2.00 × 10 -34 ), and hsa-miR-29c-3p (p = 3.00 × 10 -12 ) in blood. No significant signals were found in CSF. Analyses of genome-wide association study data for target genes of brain miRNAs showed significant association (α = 9.40 × 10 -5 ) of genetic variants in nine loci. Interpretation: We identified several miRNAs that showed highly significant differential expression in PD. Future studies may assess the possible role of the identified brain miRNAs in pathogenesis and disease progression as well as the potential of the top blood miRNAs as biomarkers for diagnosis, progression, or prediction of PD. ANN NEUROL 2019;85:835-851 P arkinson's disease (PD) is the second-most common neurodegenerative disease affecting 1% of people over the age of 60. The increasing incidence of PD in industrialized, aging populations constitutes a growing socioeconomic burden. 1 Idiopathic PD results from a combination of multiple genetic 2-4 and environmental/lifestyle factors. 5,6 However, the currently known risk factors only explain a small fraction of the phenotypic variance of PD. Likewise, PD View this article online at wileyonlinelibrary.com.

show abstract

Serum microRNA-133b is associated with low ceruloplasmin levels in Parkinson's disease

Cited by 42 publications

References 29 publications

Reduced Circulating Levels of miR-433 and miR-133b Are Potential Biomarkers for Parkinson’s Disease

Reduced Circulating Levels of miR-433 and miR-133b Are Potential Biomarkers for Parkinson’s Disease

Serum miR‐221 serves as a biomarker for Parkinson's disease

Meta‐analyses identify differentially expressed microRNAs in Parkinson's disease

Contact Info

Product

Resources

About